Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine

Show full item record



Feola , S , Russo , S , Martins , B , Lopes , A , Vandermeulen , G , Fluhler , V , De Giorgi , C , Fusciello , M , Pesonen , S , Ylösmäki , E , Antignani , G , Chiaro , J , Hamdan , F , Feodoroff , M , Grönholm , M & Cerullo , V 2022 , ' Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine ' , Frontiers in Immunology , vol. 13 , 826164 .

Title: Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
Author: Feola, Sara; Russo, Salvatore; Martins, Beatriz; Lopes, Alessandra; Vandermeulen, Gaëlle; Fluhler, Vinciane; De Giorgi, Camilla; Fusciello, Manlio; Pesonen, Sari; Ylösmäki, Erkko; Antignani, Gabriella; Chiaro, Jacopo; Hamdan, Firas; Feodoroff, Michaela; Grönholm, Mikaela; Cerullo, Vincenzo
Contributor organization: ImmunoViroTherapy Lab
Division of Pharmaceutical Biosciences
University of Helsinki
TRIMM - Translational Immunology Research Program
Drug Research Program
Faculty of Pharmacy
Helsinki Institute of Life Science HiLIFE
Digital Precision Cancer Medicine (iCAN)
Research Programs Unit
Divisions of Faculty of Pharmacy
Date: 2022-04-14
Language: eng
Number of pages: 16
Belongs to series: Frontiers in Immunology
ISSN: 1664-3224
Abstract: Oncolytic Viruses (OVs) work through two main mechanisms of action: the direct lysis of the virus-infected cancer cells and the release of tumor antigens as a result of the viral burst. In this sc.enario, the OVs act as in situ cancer vaccines, since the immunogenicity of the virus is combined with tumor antigens, that direct the specificity of the anti-tumor adaptive immune response. However, this mechanism in some cases fails in eliciting a strong specific T cell response. One way to overcome this problem and enhance the priming efficiency is the production of genetically modified oncolytic viruses encoding one or more tumor antigens. To avoid the long and expensive process related to the engineering of the OVs, we have exploited an approach based on coating OVs (adenovirus and vaccinia virus) with tumor antigens. In this work, oncolytic viruses encoding tumor antigens and tumor antigen decorated adenoviral platform (PeptiCRAd) have been used as cancer vaccines and evaluated both for their prophylactic and therapeutic efficacy. We have first tested the oncolytic vaccines by exploiting the OVA model, moving then to TRP2, a more clinically relevant tumor antigen. Finally, both approaches have been investigated in tumor neo-antigens settings. Interestingly, both genetically modified oncolytic adenovirus and PeptiCRAd elicited T cells-specific anti-tumor responses. However, in vitro cross-representation experiments, showed an advantage of PeptiCRAd as regards the fast presentation of the model epitope SIINFEKL from OVA in an immunogenic rather than tolerogenic fashion. Here two approaches used as cancer oncolytic vaccines have been explored and characterized for their efficacy. Although the generation of specific anti-tumor T cells was elicited in both approaches, PeptiCRAd retains the advantage of being rapidly adaptable by coating the adenovirus with a different set of tumor antigens, which is crucial in personalized cancer vaccines clinical setting.
Description: Publisher Copyright: Copyright © 2022 Feola, Russo, Martins, Lopes, Vandermeulen, Fluhler, De Giorgi, Fusciello, Pesonen, Ylösmäki, Antignani, Chiaro, Hamdan, Feodoroff, Grönholm and Cerullo.
Subject: 3122 Cancers
317 Pharmacy
cancer vaccines
oncolytic viruses
personalized medicine
tumor antigens
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
fimmu_13_826164.pdf 5.262Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record